Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers
|ClinicalTrials.gov Identifier: NCT00984919|
Recruitment Status : Completed
First Posted : September 25, 2009
Last Update Posted : February 15, 2016
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.
PURPOSE: This research study is looking at a biomarker, 11-dh-TXB2, in blood and urine samples from patients with prostate cancer and healthy volunteers.
|Condition or disease||Intervention/treatment|
|Prostate Cancer||Other: high performance liquid chromatography Other: laboratory biomarker analysis Other: mass spectrometry|
- To identify a potential novel marker of prostate cancer in the blood and urine, 11-dh-TXB2, to be used as a screening tool for prostate cancer as well as in detection of early relapse in patients previously treated for early-stage prostate cancer.
OUTLINE: Blood and urine samples are collected and analyzed for plasma and urinary 11-dh-TXB2 levels by HPLC and tandem-mass spectrometry.
|Study Type :||Observational|
|Actual Enrollment :||10 participants|
|Observational Model:||Case Control|
|Official Title:||Pilot Study of the Role of 11-dh-TXB2 in Prostate Cancer Screening and Diagnosis|
|Study Start Date :||November 2009|
|Actual Primary Completion Date :||January 2011|
|Actual Study Completion Date :||February 2011|
- Identification of 11-dh-TXB2 in the blood and urine [ Time Frame: 2 to 4 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00984919
|United States, Michigan|
|Barbara Ann Karmanos Cancer Institute|
|Detroit, Michigan, United States, 48201-1379|
|Principal Investigator:||Elisabeth I. Heath, MD||Barbara Ann Karmanos Cancer Institute|